Pixium Vision

Pixium Vision operates in the highly specialized retinal-prosthesis segment of medical devices, combining implant hardware, neural processing, microelectronics, computing, and clinical research. Its principal differentiation is the breadth of its platform history: IRIS1 and IRIS2 represent epiretinal approaches, while IRIS3 targets a subretinal configuration; the Prima Bionic Vision System and PRIMA program focus on partial visual restoration for people with retinal degeneration, including dry age-related macular degeneration. The company is publicly listed on Euronext Paris and has attracted European life-sciences investors including Sofinnova Partners, Omnes Capital, Abingworth, Bpifrance, and Kreos Capital. Science Corporation is an important adjacent organization because its European rollout is linked to the Prima system, but the record does not establish whether it should be treated as a competitor, commercialization partner, or successor operator. Pixium’s market position is therefore best characterized as technology-focused and clinically oriented, with limited current operating detail.

Pixium Vision’s trajectory shows a progression from academic spin-out to publicly financed medical-device developer. Founded in 2011 from work involving the Vision Institute and Université Pierre et Marie Curie, the company raised an initial venture round in 2012 and a $20.3 million Series A in 2013 led by Sofinnova Partners. It went public on Jun 18, 2014 at a reported valuation of approximately $136.4 million, then added $12.3 million in post-IPO debt from Kreos Capital in 2016 and $8.3 million in post-IPO equity in 2020. Its stated platform evolution moved from the epiretinal IRIS1 and IRIS2 systems toward the subretinal IRIS3 concept and the PRIMA/Prima Bionic Vision System for dry AMD. Employee information is sparse, with a reported range of 11–50 people and four featured current positions.